Farmacogenómica del Cáncer ; Pharmacogenomic of cancer
Gedelcan
Hospital de Fuenlabrada
Fuenlabrada, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Fuenlabrada (9)
2023
-
Postoperative Critical Care Admission Was Not Associated with Improved Postoperative Outcomes in Elective Colorectal Surgery: Secondary Analysis Of POWER Trial
Journal of Gastrointestinal Surgery, Vol. 27, Núm. 10, pp. 2187-2198
2022
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
2021
-
Institutional factors associated with adherence to enhanced recovery protocols for colorectal surgery: Secondary analysis of a multicenter study
Journal of Clinical Anesthesia, Vol. 74
2020
-
Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: Secondary analysis of POWER trial
Minerva Anestesiologica, Vol. 87, Núm. 1, pp. 13-25
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2016
2015
2012
-
Knowledge and adherence to SEGO recommendations for the prevention of cervical cancer by Spanish gynecologists in daily practice
Progresos de Obstetricia y Ginecologia, Vol. 55, Núm. 4, pp. 153-164